Erratum to “Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis”
First published: 12 October 2023
In the article titled “Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis” [1], incorrect versions of Figures 1(a) and 1(b) were published due to an error in the production process. Specifically, “baseline” and “high-efficacy DMT” on the x-axis are incorrectly labelled. In addition, the x-axis labels are displaced from the corresponding bar chart columns. The correct figures are shown below.
Figure 1 (a)
Changes of GCIPL and pRNFL thickness over time. Bar charts represent the individual GCIPL (a) and pRNFL (b) from best eye of each patient during three different time points. The thickness of GCIPL was significantly thinner during 1st-line DMT (p < 0.01) and high-efficacy DMT (p < 0.05) compared to baseline. There are no significant differences of pRNFL thickness among the three different time points. DMT: disease-modifying treatment; GCIPL: ganglion cell inner-plexiform layer; pRNFL: peripapillary retinal nerve fibre layer.
Figure 1 (b)
Changes of GCIPL and pRNFL thickness over time. Bar charts represent the individual GCIPL (a) and pRNFL (b) from best eye of each patient during three different time points. The thickness of GCIPL was significantly thinner during 1st-line DMT (p < 0.01) and high-efficacy DMT (p < 0.05) compared to baseline. There are no significant differences of pRNFL thickness among the three different time points. DMT: disease-modifying treatment; GCIPL: ganglion cell inner-plexiform layer; pRNFL: peripapillary retinal nerve fibre layer.
